ReviewCancers2021
Therapeutic Targets of KRAS in Colorectal Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Evaluating KRAS-Associated Responses to Sulfasalazine and 5-Fluorouracil in Colorectal Cancer Using Integrated 2D and PEGDA Microwell-Based 3D Tumor Models.International journal of molecular sciences · 2026Article
- Comparison of somatic mutations and clinicopathologic features of micropapillary and non-micropapillary colorectal carcinomas.BMC cancer · 2025Article
- A targeted next-generation sequencing panel for identification of clinically relevant mutation profiles in solid tumours.Scientific reports · 2025Article
- Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Intersecting evidence: Bibliometric analysis and clinical trials illuminate immunotherapy in KRAS-mutation cancer: A review.Medicine · 2024Review
- Molecular characteristics of patients with colorectal signet-ring cell carcinoma with different ABO blood groups.Heliyon · 2024Article
- IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.Journal of translational medicine · 2024Article
- Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways.Medical oncology (Northwood, London, England) · 2023Review
- Multi-omics analysis of DNA replication-associated primase polymerase (PRIMPOL) in pan-cancer: a potential target for prognosis and immune response.European journal of medical research · 2023Article
- Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial.Frontiers in oncology · 2023Article
- Mouse Models for Application in Colorectal Cancer: Understanding the Pathogenesis and Relevance to the Human Condition.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.